References
- Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on T2D prevention. Diabet Med 24, 451–463, 2007.10.1111/j.1464-5491.2007.02157.x
- Anlar HG, Bacanli M, Cal T, Aydin S, Ari N, Undeger Bucurgat U, Basaran AA, Basaran AN. Turk. Effects of cinnamic acid on complications of diabetes. J Med Sci 48, 168–177, 2018.10.3906/sag-1708-8
- Barkas F, Liamis G, Elisaf M, Anastasiou G, Liberopoulos E. Metabolically healthy obesity and risk of incident T2D in 1077 statin-treated individuals: A six-year retrospective study. Eur J Prev Cardiol 27, 2341–2344, 2020.10.1177/2047487319899191
- Barre DE, Mizier-Barre KA, Stelmach E, Hobson J, Griscti O, Rudiuk A, Muthuthevar D. Flaxseed lignan complex administration in older human T2D patients manages central obesity and prothrombosis - an invitation to further investigation into polypharmacy reduction. J Nutr Metab 2012, 585170, 2012.10.1155/2012/585170
- Barre DE, Mizier-Barre KA. Lignans’ potential in pre- and post-onset type 2 diabetes management. Curr Diabetes Rev 16, 2–11, 2020.10.2174/1573399814666180914094520
- Beg ZH, Siddiqi M. Effect of 3-hydroxy-3-methylglutaric acid on blood lipids in normal and cholesterol-fed rats. Experientia 24, 791–792, 1968.10.1007/BF02144870
- Beg ZH, Siddiqu M, Siddiqi RA. Effect of 3-hydroxy-3-methylglutaric acid on hypercholesterolemic liver. Experientia 24, 15–16, 1968.10.1007/BF02136763
- Beg ZH, Lupien PJ. In vitro and in vivo inhibition of hepatic cholesterol synthesis by 3-hydroxy-3-methylglutaric acid. Biochim Biophys Acta 260, 439–448, 1972.10.1016/0005-2760(72)90059-8
- Calabresi L, Franceschini G, Sirtori M, Gianfranceschi G, Werba P, Sirtori CR. Influence of serum triglycerides on the HDL pattern in normal subjects and patients with coronary artery disease. Atherosclerosis 84, 41–48, 1990.10.1016/0021-9150(90)90006-5
- Ceolotto G, Papparella I, Lenzini L, Sartori M, Mazzoni M, Iori E, Franco L, Gallo A, de Kreutzenberg SV, Tiengo A, Pessina AC, Avogaro A, Semplicini A. Insulin generates free radicals in human fibroblasts ex vivo by a protein kinase C-dependent mechanism, which is inhibited by pravastatin. Free Radic Biol Med 41, 473–83, 2006.10.1016/j.freeradbiomed.2006.04.01516843828
- Cicero AF, Colletti A. Role of phytochemicals in the management of metabolic syndrome. Phytomedicine 23, 1134–1144, 2016.10.1016/j.phymed.2015.11.009
- Climent E, Perez-Calahorra S, Marco-Benedi V, Plana N, Sanchez R, Ros E, Ascaso JF, Puzo J, Almagro F, Lahoz C, Civeira F, Pedro-Botet. Effect of LDL cholesterol, statins and presence of mutations on the prevalence of T2D in heterozygous familial hypercholesterolemia. J. Sci Rep 7, 5596, 2017.10.1038/s41598-017-06101-6
- Cornish SM, Chilibeck PD, Paus-Jennsen L, Biem HJ, Khozani T, Senanayake V, Vatanparast H, Little JP, Whiting SJ, Pahwa P. A randomized controlled trial of the effects of flaxseed lignan complex on metabolic syndrome composite score and bone mineral in older adults. Appl Physiol Nutr Metab 34, 89–98, 2009.10.1139/H08-142
- Cui JY, Zhou RR, Han S, Wang TS, Wang LQ, Xie XH. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis. J Clin Pharm Ther 43, 556–570, 2018.10.1111/jcpt.12690
- da Rosa MS, Seminotti B, Ribeiro CA, Parmeggiani B, Grings M, Wajner M, Leipnitz G. 3-Hydroxy-3-methylglutaric and 3-methylglutaric acids impair redox status and energy production and transfer in rat heart: relevance for the pathophysiology of cardiac dysfunction in 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency. Free Radic Res 50, 997–1010, 2016.10.1080/10715762.2016.1214952
- da Rosa-Junior NT, Parmeggiani B, Glanzel NM, de Moura Alvorcem L, Frusciante MR, Dutra Filho CS, Wajner M, Leipnitz G. In vivo evidence that bezafibrate prevents oxidative stress and mitochondrial dysfunction caused by 3-methylglutaric acid in rat liver. Biochimie 171–172, 187–196, 2020.10.1016/j.biochi.2020.03.007
- Di Padova C, Bosisio E, Cighetti G, Rovagnati P, Mazzocchi M, Colombo C, Tritapepe R. 3-Hydroxy-3-methylglutaric acid (HMGA) reduces dietary cholesterol induction of saturated bile in hamster. Life Sci 30, 1907–1914, 1982.10.1016/0024-3205(82)90471-4
- Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The Anti-inflammatory effects of statins on coronary artery disease: An updated review of the literature. Curr Cardiol Rev 13, 209–216, 2017.10.2174/1573403X13666170426104611563371528462692
- Douillard C, Mention K, Dobbelaere D, Wemeau JL, Saudubray JM, Vantyghem MC. Hypoglycaemia related to inherited metabolic diseases in adults. Orphanet J Rare Dis 7, 26, 2012.10.1186/1750-1172-7-26345888022587661
- Dos Santos Mello M, Ribas GS, Wayhs CA, Hammerschmidt T, Guerreiro GB, Favenzani JL, Sitta A, de Moura Coelho D, Wajner M, Vargas CR. Increased oxidative stress in patients with 3-hydroxy-3-methylglutaric aciduria. Mol Cell Biochem 402, 149–155, 2015.10.1007/s11010-014-2322-x25557019
- Duran M, Ketting D, Wadman SK, Jakobs C, Schutgens RB, Veder HA. Organic acid excretion in a patient with 3-hydroxy-3-methylglutaryl-CoA deficiency: facts and artefacts. Clin Chim Acta 90, 187–193, 1978.10.1016/0009-8981(78)90521-1
- Fernandes CG, da Rosa MS, Seminotti B, Pierozan P, Martell RW, Lagranha VL, Busanello EN, Leipnitz G, Wajner M. In vivo experimental evidence that the major metabolites accumulating in 3-hydroxy-3-methylglutaryl-CoA lyase deficiency induce oxidative stress in striatum of developing rats: a potential pathophysiological mechanism of striatal damage in this disorder. Mol Genet Metab 109, 144–153, 2013.10.1016/j.ymgme.2013.03.017
- Fernandes CG, Rodrigues MDN, Seminotti B, Colin-Gonzalez AL, Santamaria A, Quincozes-Santos A, Wajner M. Induction of a proinflammatory response in cortical astrocytes by the major metabolites accumulating in HMG-CoA lyase deficiency: the role of ERK signaling pathway in cytokine release. Mol Neurobiol 53, 3586–3595, 2016.10.1007/s12035-015-9289-9
- Francesconi M, Galzigna L, Plebani M, Furlanetto V, Fabris R, Deana R. Effect of 3-hydroxy-3-methylglutarate treatment on plasma ketone bodies, triglycerides, and HDL-cholesterol in streptozotocin-diabetic rats. Clin Biochem 20, 201–205, 1987.10.1016/S0009-9120(87)80121-2
- Frank J, Eliasson C, Leroy-Nivard D, Budek A, Lundh T, Vessby B, Aman P, Kamal-Eldin A. Dietary secoisolariciresinol diglucoside and its oligomers with 3-hydroxy-3-methyl glutaric acid decrease vitamin E levels in rats. Brit J Nutr 92, 169–176, 2004.10.1079/BJN2004115415231000
- Gastaldi G, Philippe J. Statins and diabetes: The plot thickens. J Gen Intern Med 30, 1572–1573, 2015.10.1007/s11606-015-3399-y461793125986140
- Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 58, 614–618, 2004.10.1016/j.biopha.2004.09.00515589072
- Hafizur RM, Hameed A, Shukrana M, Raza SA, Chishti S, Kabir N, Siddiqui RA Cinnamic acid exerts anti-diabetic activity by improving glucose tolerance in vivo and by stimulating insulin secretion in vitro. Phytomed 22, 297–300, 2015.10.1016/j.phymed.2015.01.00325765836
- Hallund J, Ravn-Haren G, Bugel S, Tholstrup T, Tetens I. A lignan complex isolated from flaxseed does not affect plasma lipid concentrations or antioxidant capacity in healthy postmenopausal women. J Nutr 136, 112–116, 2006.10.1093/jn/136.1.11216365068
- Hallund J, Tetens I, Bugel S, Tholstrup T, Bruun JM. The effect of a lignan complex isolated from flaxseed on inflammation markers in healthy postmenopausal women. Nutr Metab Cardiovasc Dis 18, 497–502, 2008.10.1016/j.numecd.2007.05.00718502107
- Hammond J, Wilcken B. 3-hydroxy-3-methylglutaric, 3-methylglutaconic and 3-methylglutaric acids can be non-specific indicators of metabolic disease. J Inherit Metab Dis 7 Suppl 2, 117–118, 1984.10.1007/978-94-009-5612-4_33
- Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb 25, 771–782, 2018.10.5551/jat.RV17023
- Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 105, 4S–14S, 1998.10.1016/S0002-9343(98)00205-8
- Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. The role of polyphenolic compounds in the diet as inhibitors of platelet function. Proc Nutr Soc 62, 469–478, 2003.10.1079/PNS200325314506895
- Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 20, 2140–2147, 2000.10.1161/01.ATV.20.9.2140
- Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative stress and inflammation: What polyphenols can do for us? Oxid Med Cell Longev 2016, 7432797, 2016.10.1155/2016/7432797505598327738491
- Ikezaki H, Furusyo N, Yokota Y, Ai M, Asztalos BF, Murata M, Hayashi J, Schaefer EJ. Small dense low-density lipo-protein cholesterol and carotid intimal medial thickness progression. J Atheroscler Thromb 27, 1108–1122, 2020.10.5551/jat.54130758590932281547
- Isley WL, Park Y, Harris WS. The effect of high dose simvastatin on, platelet size in patients with, T2D mellitus. Platelets 17, 292–295, 2006.10.1080/0953710060074649016928600
- Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160–1164, 2001.10.1126/science.105934411349148
- Jeong HS, Hong SJ, Son S, An H, Kook H, Joo HJ, Park JH, Yu CW, Lim DS. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up. Cardiovasc Diabetol 18, 162, 2019.10.1186/s12933-019-0969-z686879731752850
- Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol 58, 303–309, 2004.10.1111/j.1365-2125.2004.02142.x
- Jones DE, Perez L, Ryan RO. 3-Methylglutaric acid in energy metabolism. Clin Chim Acta 502, 233–239, 2020.10.1016/j.cca.2019.11.006
- Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 287, 598–605, 2002.10.1001/jama.287.5.598
- Khan AN, Umar S, Khan SY, Siddiqi M. Hypocholesterolaemic and hypolipidaemic role of 3-hydroxy-3-methylglutarate in rabbits fed on an atherogenic diet. Biochem J 128, 41P–42P, 1972.10.1042/bj1280041Pb
- Kim SY, Koo YK, Koo JY, Ngoc TM, Kang SS, Bae K, Kim YS, Yun-Choi HS. Platelet anti-aggregation activities of compounds from Cinnamomum cassia. J Med Food 13, 1069–1074, 2010.10.1089/jmf.2009.1365
- Kim J, Lee H, An J, Song Y, Lee CK, Kim K, Kong H. Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia. Front Microbiol 10, 1947, 2019.10.3389/fmicb.2019.01947
- Konig GM, Wright AD, Keller WJ, Judd RL, Bates S, Day C. Hypoglycaemic activity of an HMG-containing flavonoid glucoside, chamaemeloside, from Chamaemelum nobile. Planta Med 64, 612–614, 1998.10.1055/s-2006-957532
- Kouvari M, Panagiotakos DB, Yannakoulia M, Georgousopoulou E, Critselis E, Chrysohoou C, Tousoulis D, Pitsavos C; ATTICA Study Investigators. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: The ATTICA cohort study. Metabolism 93, 18–24, 2019.10.1016/j.metabol.2019.01.003
- Lee IT, Sheu WH, Lin SY, Lee WJ, Song YM, Liu HC. Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. J Diabetes Complications 16, 382–385, 2002.10.1016/S1056-8727(02)00184-8
- Lee MK, Park YB, Moon SS, Bok SH, Kim DJ, Ha TY, Jeong TS, Jeong KS, Choi MS. Hypocholesterolemic and antioxidant properties of 3-(4-hydroxyl) propanoic acid derivatives in high-cholesterol fed rats. Chem Biol Interact 170, 9–19, 2007.10.1016/j.cbi.2007.06.03717662703
- Li H, Lin H, Zhao H, Xu Y, Cheng Y, Shen P, Zhan S. Statins use and risk of new-onset diabetes in hypertensive patients: a population-based retrospective cohort study in Yinzhou district, Ningbo city, People’s Republic of China. Ther Clin Risk Manag 14, 823–832, 2018.10.2147/TCRM.S158850
- Lodovici M, Bigagli E, Luceri C, Mannucci E, Rotella CM, Raimondi L Gender-related drug effect on several markers of oxidation stress in diabetes patients with and without complications. Eur J Pharmacol 766, 86–90, 2015.10.1016/j.ejphar.2015.09.041
- Lupien PJ, Brun D, Moorjani S. Effectiveness of 3-hydroxy-3-methylglutaric acid in familial hypercholesterolaemia. Lancet 1(7814), 1256, 1973a.10.1016/S0140-6736(73)90575-8
- Lupien PJ, Tremblay M, Beg ZH. 3-Hydroxy-3-methylglutaric acid: protective action in experimental atherosclerosis in rabbits. Atherosclerosis 18, 407–416, 1973b.10.1016/0021-9150(73)90071-3
- Lupien PJ, Brun D, Moorjani S. Long-term treatment of homozygous familial hypercholesterolaemia with 3-hydroxy-3-methylglutaric acid. Lancet 1(8058), 283–284, 1978.10.1016/S0140-6736(78)90539-1
- Lupien PJ, Moorjani S, Brun D, Bielmann I. Effects of 3-hydroxy-3-methylglutaric acid on plasma and low-density lipoprotein cholesterol levels in familial hypercholesterolemia. J Clin Pharmacol 19, 120–126, 1979.10.1002/j.1552-4604.1979.tb02469.x217894
- Macedo AF, Douglas I, Smeeth L, Forbes H, Ebrahim S Statins and the risk of T2D mellitus: cohort study using the UK clinical practice research datalink. BMC Cardiovasc Disord 14, 85, 2014.10.1186/1471-2261-14-85411829425022519
- Maksymets T, Sorochka M, Bondarenko O, Karpyshyn N, Bochar O, Sklyarov Y. Comparison of metabolic profile of obese non-diabetic patients with coronary artery disease depending on atorvastatin dose. Wiad Lek. 272, 846–850, 2019.10.36740/WLek201905122
- Milajerdi A, Sadeghi A, Mousavi SM, Larijani B, Esmaillzadeh A. Influence of statins on circulating inflammatory cytokines in patients with abnormal glucose homeostasis: a meta-analysis of data from randomized controlled trials. Clin Ther 42, e13–e31, 2020.10.1016/j.clinthera.2019.12.00931955966
- Mnafgui K, Derbali A, Sayadi S, Gharsallah N, Elfeki A, Allouche N. Anti-obesity and cardioprotective effects of cinnamic acid in high fat diet-induced obese rats. J Food Sci Technol 52, 4369–4377, 2015.10.1007/s13197-014-1488-2448657026139902
- Mogadam M. Do statins increase the risk of diabetes or is it guilt by association? Curr Opin Endocrinol Diabetes Obes 21, 140–145, 2014.10.1097/MED.000000000000005024569555
- Muir AD. Flax lignans--analytical methods and how they influence our understanding of biological activity. J AOAC Int 89, 1147–1157, 2006.10.1093/jaoac/89.4.1147
- Nierenberg JL, He J, Li C, Gu X, Shi M, Razavi AC, Mi X, Li S, Bazzano LA, Anderson AH, He H, Chen W, Kinchen JM, Rebholz CM, Coresh J, Levey AS, Inker LA, Shlipak M, Kelly TN. Novel associations between blood metabolites and kidney function among Bogalusa Heart Study and Multi-Ethnic Study of Atherosclerosis participants. Metabolomics 15, 149, 2019.10.1007/s11306-019-1613-3702145531720858
- Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 5, 928–948, 2013.10.3390/nu5030928370532723507795
- Ohara M, Nagaike H, Goto S, Fukase A, Tanabe Y, Tomoyasu M, Yamamoto T, Hayashi T, Fukui T, Hirano T. Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with T2D. Diabetes Res Clin Pract 139, 253–261, 2018.10.1016/j.diabres.2018.02.01729501829
- Pan A, Sun J, Chen Y, Ye X, Li H, Yu Z, Wang Y, Gu W, Zhang X, Chen X, Demark-Wahnefried W, Liu Y, Lin X. Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, crossover trial. PLoS One 2, e1148, 2007.10.1371/journal.pone.0001148204857717987126
- Pan A, Demark-Wahnefried W, Ye X, Yu Z, Li H, Qi Q, Sun J, Chen Y, Chen X, Liu Y, Lin X. Effects of a flaxseed-derived lignan supplement on C-reactive protein, IL-6 and retinol-binding protein 4 in type 2 diabetic patients. Br J Nutr 101, 1145–1149, 2009.10.1017/S000711450806152718775100
- Paradela-Dobarro B, Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L, Garcia-Acuna JM, Aguiar-Souto P, Jacquet-Hervet M, Reino-Maceiras MV, Gonzalez-Juanatey JR, Alvarez E. Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: evidence in patients with acute myocardial infarction. Eur J Pharm Sci, 49, 512–518, 2013.10.1016/j.ejps.2013.05.00123665412
- Perego F, Davi G. Beyond hyperglycemia in diabetes: role of statin treatment on thrombogenesis triggered by inflammation: Editorial to: “Impact of statins on the coagulation status of T2D patients evaluated by a novel thrombin-generations assay” by P. Ferroni et al. Cardiovasc Drugs Ther 26, 281–284, 2012.10.1007/s10557-012-6398-922585309
- Peterson J, Dwyer J, Adlercreutz H, Scalbert A, Jacques P, McCullough ML. Dietary lignans: physiology and potential for cardiovascular disease risk reduction. Nutr Rev 68, 571–603, 2010.10.1111/j.1753-4887.2010.00319.x295131120883417
- Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/T2D. Metabolism 51, 334–342, 2002.10.1053/meta.2002.30510
- Postula M, Rosiak M, Kaplon-Cieslicka A, Kondracka A, Trzepla E, Filipiak KJ, Czlonkowski A, Opolski G. Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with T2D? Cardiol J 19, 494–500, 2012.10.5603/CJ.2012.0090
- Prabhakar PK, Doble M. Interaction of cinnamic acid derivatives with commercial hypoglycemic drugs on 2-deoxyglucose uptake in 3T3-L1 adipocytes. J Agric Food Chem 59, 9835–9844, 2011.10.1021/jf2015717
- Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 99, 1355–1362, 1999.10.1161/01.CIR.99.10.1355
- Prasad K. Hypocholesterolemic and antiatherosclerotic effect of flaxseed lignan complex isolated from flaxseed. Atherosclerosis 179, 269–275, 2005.10.1016/j.atherosclerosis.2004.11.012
- Prasad K, Khan AS, Shoker M. Flaxseed and its components in treatment of hyperlipidemia and cardiovascular disease. Int J Angiol 29, 216–222, 2020.10.1055/s-0040-1709129
- Riche DM, McClendon KS. Role of statins for the primary prevention of cardiovascular disease in patients with T2D mellitus. Am J Health Syst Pharm 64, 1603–1610, 2007.10.2146/ajhp060397
- Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 173, 1–12, 2004.10.1016/S0021-9150(03)00239-9
- Sasaki A, Horiuchi N, Hasegawa K, Uehara M. Mortality from coronary heart disease and cerebrovascular disease and associated risk factors in diabetic patients in Osaka District, Japan. Diabetes Res Clin Pract 27, 77–83, 1995.10.1016/0168-8227(94)01018-U
- Scharnagl H, Winkler K, Mantz S, Baumstark MW, Wieland H, Marz W. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and T2D mellitus. Exp Clin Endocrinol Diabetes 112, 269–277, 2004.10.1055/s-2004-81797515146374
- Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group. Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: Insights from the TECOS Trial. Diabetes Care 40, 1763–1770, 2017.10.2337/dc17-1091
- Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109, 18–26, 2004.10.1161/01.CIR.0000129505.34151.23
- Sirtori CR. The pharmacology of statins. Pharmacol Res 88, 3–11, 2014.10.1016/j.phrs.2014.03.002
- Skoumas I, Masoura C, Aznaouridis K, Metaxa V, Tsokanis A, Papadimitriou L, Tousoulis D, Pitsavos C, Stefanadis C. Impact of cardiometabolic risk factors on major cardiovascular events in patients with familial combined hyperlipidemia. Circ J. 77, 163–168, 2018.10.1253/circj.CJ-12-0320
- Sone H, Takahashi A, Shimano H, Ishibashi S, Yoshino G, Morisaki N, Saito Y, Kawazu S, Teramoto T, Fujita T, Shiba T, Iwamoto Y, Kuzuya N, Akanuma Y, Yamada N. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sciences 71, 2403–2412, 2002.10.1016/S0024-3205(02)02038-6
- Sugiyama T, Tsugawa Y, Tseng CH, Kobayashi Y, Shapiro MF. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med, 174, 1038–1045, 2014.10.1001/jamainternmed.2014.1927
- Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22, 1452–1458, 2002.10.1161/01.ATV.0000030360.72503.56
- Tirosh A, Shai I, Bitzur R, Kochba I, Tekes-Manova D, Israeli E, Shochat T, Rudich A. Changes in triglyceride levels over time and risk of T2D in young men. Diabetes Care 31, 2032–2037, 2008.10.2337/dc08-0825
- Vamecq J, Papegay B, Nuyens V, Boogaerts J, Leo O, Kruys V. Mitochondrial dysfunction, AMPK activation and peroxisomal metabolism: A coherent scenario for non-canonical 3-methylglutaconic acidurias. Biochimie 168, 53–82, 2020.10.1016/j.biochi.2019.10.004
- Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 38, 189–197, 2001.10.1016/S0161-5890(01)00042-6
- Wang H, Li Q, Deng W, Omari-Siaw E, Wang Q, Wang S, Wang S, Cao X, Xu X, Yu J. Self-nanoemulsifying drug delivery system of trans-cinnamic acid, formulation development and pharmacodynamic evaluation in alloxan-induced type 2 diabetic rat model. Drug Develop Res 76, 82–93, 2015.10.1002/ddr.21244
- Wang L, Shi J, Zhang Y. Influences of simvastatin on vascular endothelial function of patients with coronary heart disease complicated with congestive heart failure. Eur Rev Med Pharmacol Sci 17, 1590–1593, 2013.
- Witherup KM, McLaughlin JL, Judd RL, Ziegler MH, Medon PJ, Keller WJ. Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides). J Nat Prod 58, 1285–1290, 1995.10.1021/np50122a023
- Wysocki SJ, Wilkinson SP, Hahnel R, Wong CY, Panegyres PK. 3-Hydroxy-3-methylglutaric aciduria, combined with 3-methylglutaconic aciduria. Clin Chim Acta 70, 399–406, 1976.10.1016/0009-8981(76)90353-3
- Yamagishi S, Matsui T, Sato T, Takeuchi M. Protective role of pravastatin in the pathogenesis of the metabolic syndrome. Med Hypotheses 66, 609–611, 2006.10.1016/j.mehy.2005.08.004
- Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with T2D mellitus. J Atheroscler Thromb 15, 269–275, 2008.10.5551/jat.E562
- Yoo KM, Lee C, Lo YM, Moon B. The hypoglycemic effects of American red ginseng (Panax quinquefolius L.) on a diabetic mouse model. J Food Sci 77, H147–H152, 2012.10.1111/j.1750-3841.2012.02748.x
- Yousufzai SY, Siddiqi M. 3-Hydroxy-3-methylglutaric acid and triton-induced hyperlipidemia in rats. Experientia 32, 1178–1179, 1976a.10.1007/BF01927612
- Yousufzai SY, Siddiqi M. 3-hydroxy-3-methylglutaric acid and experimental atherosclerosis in rats. Experientia 32, 1033–1034, 1976b.10.1007/BF01933955
- Yousufzai SY, Siddiqi M. Tissue lipid responses to 3-hydroxy-3-methylglutaric acid with different dietary fats. Lipids 12, 258–261, 1977.10.1007/BF02533343
- Yusufi AN, Siddiqi M. Studies on the hypolipidemic and hypocholesterolemic effect of 3-hydroxy-3-methylglutaric acid in rabbits. Atherosclerosis 20, 517–526, 1974.10.1016/0021-9150(74)90032-X
- Zhang W, Wang X, Liu Y, Tian H, Flickinger B, Empie MW, Sun SZ. Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercholesterolaemic subjects. Br J Nutr 99, 1301–1309, 2008.10.1017/S000711450787164918053310